Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 2Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pheochromocytoma 1Paraganglioma 1Oligometastatic Prostate Cancer (OMPC) 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune System Diseases 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Carboplatin 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Sunitinib 2Standard of Care 2Riluzole 2Radiation Dose Hypofractionation 2Prednisone 2Pluvicto 2Mitomycin 2LDP-02 2Infliximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urogenital Neoplasms × Lutetium-177 × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡